Efficacy of liraglutide 3 mig therapy in obesity and associated diseases

Abstract

Obesity is a chronic disease associated with cardiometabolic risk factors, primarily cardiovascular diseases and type 2 diabetes mellitus. In 2016,Russiaregistered a new drug for treating obese patients liraglutide 3.0 mg, which is an analogue of human glucagon-like peptide-1. Given the urgency of the problem, we present a clinical case that shows the efficacy of therapy with liraglutide 3.0 mg daily in a patient with obesity, and its effect on metabolic risk factors.

Keywords

• obesity
• liraglutide 3.0 mg once daily
• analogue of human glucagon-like peptide-1